MNMD (Mind Medicine) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Mind Medicine is: No Data: Cannot be evaluated.

Competitive Comparison of Mind Medicine's Risk Assessment

For the Biotechnology subindustry, Mind Medicine's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Risk Assessment falls into.

Mind Medicine (NAS:MNMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Mind Medicine Risk Assessment Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

MMQ:Germany

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

Executives

Mark Sullivan	officer: Chief Legal Officer	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Robert Barrow	director, officer: Chief Executive Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin	officer: Chief Medical Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao	officer: VP, Controller&Acct Principal	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Schond L. Greenway	officer: Chief Financial Officer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Carol A Vallone	director	490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs	director	5 GIRALDA FARMS, MADISON NJ 07940
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal	director	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu	officer: Chief Legal Officer&Secretary	6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli	director, officer: Executive President	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007